NCT00752505 - A Study To Assess Esreboxetine's Effect On Concentration, Memory, Decision Making And Problem Solving In Patients With Fibromyalgia. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions

Fibromyalgia

Interventions

DRUG

Esreboxetine

Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing

DRUG

Esreboxetine

Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing

Trial Locations (7)

32541

Pfizer Investigational Site, Destin

32547

Pfizer Investigational Site, Fort Walton Beach

48025

Pfizer Investigational Site, Bingham Farms

48109

Pfizer Investigational Site, Ann Arbor

73103

Pfizer Investigational Site, Oklahoma City

75231

Pfizer Investigational Site, Dallas

78756

Pfizer Investigational Site, Austin